Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

Beta Agonist Nebulization in Non Invasively Ventilated COPD Patients: Safety, and Therapeutic Efficacy Range.

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-10-09
Last Posted Date
2016-05-16
Lead Sponsor
University Hospital, Tours
Target Recruit Count
43
Registration Number
NCT01958814
Locations
🇫🇷

Service de Réanimation Médicale - CHR d'Orléans, Orléans, France

🇫🇷

Service de Réanimation, Poitiers, France

🇫🇷

CHRU de Tours, Tours, France

Influence of Salbutamol on Emotional and Cognitive Functions in Healthy Subjects

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-10-08
Last Posted Date
2014-12-16
Lead Sponsor
Prof. Dominique de Quervain, MD
Target Recruit Count
40
Registration Number
NCT01957293
Locations
🇨🇭

University of Basel, Division of Cognitive neuroscience, Basel, Switzerland

Comparison of Nebulizers in ED in Pediatric Asthma Patients

First Posted Date
2013-09-26
Last Posted Date
2021-04-08
Lead Sponsor
Seton Healthcare Family
Target Recruit Count
40
Registration Number
NCT01951378
Locations
🇺🇸

Dell Children's Medical Center of Central Texas, Austin, Texas, United States

Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

First Posted Date
2013-08-14
Last Posted Date
2015-01-01
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
152
Registration Number
NCT01922271
Locations
🇩🇪

Novartis Investigative Site, Sonneberg, Germany

Dose-Response of Salmeterol in Children

First Posted Date
2013-07-24
Last Posted Date
2014-10-07
Lead Sponsor
University of Florida
Target Recruit Count
10
Registration Number
NCT01907334
Locations
🇺🇸

University of Florida Asthma Research Lab, Gainesville, Florida, United States

Salbutamol, Pharmacogenetics and Breathing Mechanics

First Posted Date
2013-07-19
Last Posted Date
2016-11-02
Lead Sponsor
University of British Columbia
Target Recruit Count
94
Registration Number
NCT01903785
Locations
🇨🇦

Environmental Physiology Laboratory, University of British Columbia, Vancouver, British Columbia, Canada

Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease

Phase 1
Completed
Conditions
First Posted Date
2013-07-11
Last Posted Date
2014-12-03
Lead Sponsor
Duke University
Target Recruit Count
5
Registration Number
NCT01895998
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-06-25
Last Posted Date
2019-07-15
Lead Sponsor
Duke University
Target Recruit Count
16
Registration Number
NCT01885936
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2013-06-19
Last Posted Date
2023-11-29
Lead Sponsor
University of Arizona
Target Recruit Count
32
Registration Number
NCT01880723
Locations
🇺🇸

Department of Pharmacy Practice and Science, University of Arizona, Tucson, Arizona, Tucson, Arizona, United States

Albuterol in Individuals With Late Onset Pompe Disease (LOPD)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-05-22
Last Posted Date
2019-07-05
Lead Sponsor
Duke University
Target Recruit Count
8
Registration Number
NCT01859624
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath